Alexander Luft

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip, Nasser K. Altorki, Caicun Zhou et al. · The Lancet · 2021 · 1.5K citations

Medicine, Oncology, Pharmacology +13

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Charles M. Rudin, Mark M. Awad, Alejandro Navarro et al. · Journal of Clinical Oncology · 2020 · 759 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

Martin Reck, Igor Bondarenko, Alexander Luft et al. · Annals of Oncology · 2012 · 610 citations · Full text

Medicine, Oncology, Pharmacology +11

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

Silvia Novello, Dariusz M. Kowalski, Alexander Luft et al. · Journal of Clinical Oncology · 2023 · 512 citations · Full text

Medicine, Oncology, Pharmacology +17

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

Melissa L. Johnson, Byoung Chul Cho, Alexander Luft et al. · Journal of Clinical Oncology · 2022 · 434 citations · Full text

Medicine, Oncology, Pharmacology +17